Dose response of nafamostat mesylate for anticoagulation monitoring in pediatric critical care during continuous venovenous hemodiafiltration.

ABSTRACT: Nafamostat mesylate (NM) is increasingly used as an alternative anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in pediatric intensive care, especially when unfractionated heparin or regional citrate is contraindicated. However, evidence regarding optimal monitoring of its anticoagulant effects remains limited. This study aimed to investigate the association between NM infusion rate and coagulation parameters-specifically activated clotting time (ACT) and activated partial thromboplastin time (aPTT)-in critically ill pediatric patients receiving CVVHDF, and to examine how hepatic function and transfusion status may influence this relationship. In this retrospective study of 99 patients, we analyzed 340 matched data pairs of NM infusion orders and coagulation test resu

SUBMITTER: Lee S 

PROVIDER: S-EPMC12748554 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature